RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.94%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$977M
AUM Growth
+$977M
(+20%)
Cap. Flow
+$140M
Cap. Flow
% of AUM
14.32%
Top 10 Holdings %
Top 10 Hldgs %
25.96%
Holding
96
New
4
Increased
44
Reduced
31
Closed
7
Top Buys
| 1 |
Nektar Therapeutics
NKTR
|
$20M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$15.3M |
| 3 |
Incyte
INCY
|
$15.1M |
| 4 |
AET
Aetna Inc
AET
|
$12.8M |
| 5 |
Sangamo Therapeutics
SGMO
|
$11.3M |
Top Sells
| 1 |
AbbVie
ABBV
|
$12.7M |
| 2 |
Biogen
BIIB
|
$8.5M |
| 3 |
CELG
Celgene Corp
CELG
|
$6.81M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
$6.58M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$6.21M |
Sector Composition
| 1 | Healthcare | 91.68% |
| 2 | Financials | 1.43% |
| 3 | Energy | 0.15% |
| 4 | Technology | 0.13% |
| 5 | Communication Services | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADMS
51
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $8.48M | 0.87% |
328,193
+118,549
| +57% | +$3.06M |
|
52
Xencor
XNCR
$594M
| $8.01M | 0.82% |
216,443
-83,557
| -28% | -$3.09M |
|
53
Centene
CNC
$14.8B
| $8.01M | 0.82% |
130,000
| – | – |
|
54
Johnson & Johnson
JNJ
$429B
| $7.28M | 0.75% |
+60,000
| New | +$7.28M |
|
55
MacroGenics
MGNX
$121M
| $6.71M | 0.69% |
325,000
+25,000
| +8% | +$516K |
|
|
56
AbbVie
ABBV
$374B
| $6.49M | 0.66% |
70,000
-136,700
| -66% | -$12.7M |
|
57
Regeneron Pharmaceuticals
REGN
$59.8B
| $5.87M | 0.6% |
17,000
-17,000
| -50% | -$5.87M |
|
58
Omnicell
OMCL
$1.51B
| $5.79M | 0.59% |
110,375
+51,930
| +89% | +$2.72M |
|
|
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.58M | 0.57% |
203,181
| – | – |
|
60
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $4.9M | 0.5% |
350,000
| – | – |
|
61
Rigel Pharmaceuticals
RIGL
$710M
| $4.82M | 0.49% |
170,328
+8,551
| +5% | +$242K |
|
|
AERI
62
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $4.73M | 0.48% |
70,000
+30,000
| +75% | +$2.03M |
|
|
MDCO
63
DELISTED
Medicines Co
MDCO
| $4.04M | 0.41% |
110,000
+10,000
| +10% | +$367K |
|
|
64
Biogen
BIIB
$20.8B
| $3.77M | 0.39% |
13,000
-29,300
| -69% | -$8.5M |
|
|
DPLO
65
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $3.64M | 0.37% |
+142,364
| New | +$3.64M |
|
|
VRAY
66
DELISTED
ViewRay, Inc.
VRAY
| $3.58M | 0.37% |
516,623
+184,238
| +55% | +$1.27M |
|
67
Acadia Pharmaceuticals
ACAD
$4.34B
| $3.36M | 0.34% |
220,000
-50,000
| -19% | -$763K |
|
|
ZGNX
68
DELISTED
Zogenix, Inc.
ZGNX
| $2.21M | 0.23% |
50,000
| – | – |
|
|
ACHN
69
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $1.75M | 0.18% |
617,800
-50,000
| -7% | -$141K |
|
|
CMRX
70
DELISTED
Chimerix, Inc.
CMRX
| $1.63M | 0.17% |
342,000
| – | – |
|
|
PVLA
71
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $1.52M | 0.16% |
3,750
| – | – |
|
|
VIRX
72
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $907K | 0.09% |
12,218
-642
| -5% | -$47.7K |
|
73
Adverum Biotechnologies
ADVM
$68.2M
| $816K | 0.08% |
15,397
+2,696
| +21% | +$143K |
|
74
Exxon Mobil
XOM
$477B
| $563K | 0.06% |
6,804
-1,722
| -20% | -$142K |
|
75
Chevron
CVX
$318B
| $472K | 0.05% |
3,733
-415
| -10% | -$52.5K |
|